Why the study?
Does thyroxine treatment increase monolysocardiolipin acyltransferase activity and cardiolipin remodeling in rat hearts?
Does thyroxine treatment increase monolysocardiolipin acyltransferase activity and cardiolipin remodeling in rat hearts?
Thyroxine regulates the acylation of cardiac monolysocardiolipin, suggesting monolysocardiolipin acyltransferase may be a rate-limiting enzyme for cardiolipin remodeling in the heart.
Answers are grounded in this paper and cite their sources.
Thyroxine boosts cardiolipin remodeling in rat hearts; leaves open translation to human cardiac metabolism or thyroid therapy.
Treatment of rats with thyroxine has been shown to elevate the biosynthesis and content of cardiolipin in the heart [Cao, Cheng, Angel and Hatch (1995) Biochim. Biophys. Acta 1256, 241-244]. Treatment with thyroxine resulted in a 1.8-fold increase (P < 0.025) in [1-14C]linoleate and a 1.7-fold increase (P < 0.025) in [1-14C]oleate incorporated into cardiolipin in perfused hearts, compared with controls. The mechanism for the elevation in incorporation of unsaturated fatty acids into cardiolipin was a 1.6-fold (P < 0.025) increase in mitochondrial monolysocardiolipin acyltransferase activity. The results demonstrate that the acylation of cardiac monolysocardiolipin is regulated by thyroid hormone. Thus an elevation in cardiolipin biosynthesis is accompanied by an elevation in monolysocardiolipin acyltransferase activity to maintain the appropriate molecular species composition of cardiolipin in the cardiac mitochondrial membrane. We postulate that monolysocardiolipin acyltransferase might be a rate-limiting enzyme for the molecular remodelling of cardiolipin in the heart.
No takes yet. Share an insight, caveat, or question.
Mutter et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: